Villere ST Denis J & Co. LLC lessened its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 479,447 shares of the biotechnology company’s stock after selling 1,360 shares during the […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) updated its FY23 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $5.10-5.25 for the period, compared to the consensus estimate of $4.97. The company issued revenue guidance of $124-126 million, compared to the consensus revenue estimate of $127.17 million. Wall Street Analyst Weigh […]
Stephens Investment Management Group LLC lifted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 455,089 shares of the biotechnology company’s stock after acquiring an additional 673 shares during the quarter. Stephens Investment […]
Rice Hall James & Associates LLC grew its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 288,345 shares of the biotechnology company’s stock after purchasing an additional 2,711 shares during the quarter. […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) – Analysts at Zacks Research reduced their Q3 2023 EPS estimates for shares of Ligand Pharmaceuticals in a research note issued to investors on Tuesday, August 22nd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $0.24 per share for the quarter, down from […]